Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b5d1de0cb099ee72980dadb3b90d66d8 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-732 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2896 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2818 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-16 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
filingDate |
2005-05-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7838095a3ec1fb50d615dff1bc3234ae http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_16a9486d6f73deb42105cce2e43953ca http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_15ac8af14913abc399d60c871455e7b9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dac2a9b37ebb9927e7ed745c8cdf6b76 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_923f091b2263383cec1a8b8ccf923840 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3f1ab7d34a2f360bb3979400fcf21859 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e80bec2fe6f83535192f9405a67bc9ad http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_560113d1fd959b39b24f8ba21a67ed8a |
publicationDate |
2005-12-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
CA-2566745-A1 |
titleOfInvention |
Methods of treating cancer using il-21 and monoclonal antibody therapy |
abstract |
Methods for treating cancer by co-administering a therapeutic monoclonal antibody with IL-21 are described. Exemplary monoclonal antibodies that can be used are rituximab, trastuzumab and anti-CTLA-4 antibodies. The enhanced antitumor of the combination therapy is particularly useful for patient populations that are recalcitrant to monoclonal therapy, relapse after treatment with monoclonal antibodies or where the enhanced IL-21 antitumor effect reduces toxicities associated with treatment using the monoclonal antibodies. |
priorityDate |
2004-05-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |